Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.
Marth C, Lorusso D, Bidziński M, Scollo P, Vardar MA, Oaknin A, Kaen DL, Nogueira-Rodrigues A, Miller DS, Hasegawa K, MacKay H, Moore RG, Santin AD, Yunokawa M, Romero I, Pignata S, Baron-Hay S, Kim YM, Amit A, Ghamande S, Danska-Bidzinska A, Tarnawski R, Wang PH, Yu Z, Slomovitz BM, Okpara CE, McKenzie J, Meng R, Orlowski R, Makker V.
Marth C, et al. Among authors: romero i.
Int J Gynecol Cancer. 2026 Apr 12;36(7):104693. doi: 10.1016/j.ijgc.2026.104693. Online ahead of print.
Int J Gynecol Cancer. 2026.
PMID: 42167105
Free article.